Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Positive concordance of KRAS alterations between ctDNA and tissue was negatively affected by a longer time period between blood and tissue sampling and was higher in colorectal cancer than in other malignancies. 31199507

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 AlteredExpression BEFREE Combining clinical factors and COX-2/C-MET/KRAS expression status, our models provided accurate prognostic information in CRC. 30720004

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Asymmetric mutant-enriched polymerase chain reaction and quantitative DNA melting analysis of KRAS mutation in colorectal cancer. 31782995

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE <b>Results & conclusion:</b> The genotype CT of rs8720 was significantly increased risk of CRC, decreased overall survival and event-free survival, and KRAS mRNA and protein expressions were significantly increased in individuals with rs8720 CT, TT genotype. rs8720 may be an important factor in CRC development and prognosis. 31729889

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Current clinical guidelines recommend mutation analysis for select codons in KRAS and NRAS exons 2, 3, and 4 and BRAF V600E to guide therapy selection and prognostic stratification in advanced colorectal cancer. 31589789

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE The G12D KRAS mutation and CR-1 abnormalities are significantly associated as two signature biomarkers with potential clinical characteristics for the detection of CRC development. 31692030

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Collectively, our study highlights the importance of REG4 in promoting CSCs properties induced by KRAS mutation, and provides a new therapeutic strategy for CRC harboring both APC and KRAS mutations. 31605540

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 Biomarker BEFREE To overcome this limitation, we used cetuximab and panitumumab to redirect Fcγ chimeric receptor (CR) T cells against KRAS-mutated HCT116 colorectal cancer (CRC) cells. 31396956

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE The KRAS mutation is common in colorectal cancer, however the correlation between KRAS status and micrometastases has not been thoroughly clarified. 31720935

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 Biomarker BEFREE In this review, we will present up to date information on the role of miRNA-31-3p and miR-31-5p in CRC with a particular focus in treatment response of metastatic K-RAS wild-type CRC treated with anti-EGFR molecules. 31786833

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 Biomarker BEFREE Metastatic Profile of Colorectal Cancer: Interplay Between Primary Tumor Location and KRAS Status. 30737098

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE LY3214996 also exhibited synergistic combination benefit with a pan-RAF inhibitor in a KRAS-mutant colorectal cancer xenograft model. 31744895

2020

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE The strategies to target energy metabolism for the metabolic alterations in mutated KRAS CRC are also introduced. 30341899

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 Biomarker BEFREE m-KRAS is associated with worse OS in patients presenting with colorectal cancer and liver metastases undergoing resection of the primary tumor and metastatic disease. 30276588

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Our findings may shed light on the mechanism of AR in CRC, namely, that the PT harbored the same mutations as the AR and the lesions in both cases harbored the KRAS G13D mutation. 30896620

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 AlteredExpression BEFREE To better understand the cellular reprogramming which occurs in mutant KRAS cells, we have undertaken a systems-level analysis of four CRC cell lines which express either wild type (wt) KRAS or the oncogenic KRAS<sup>G13D</sup> allele (mtKRAS). 31133691

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 Biomarker BEFREE Whole Transcriptome Analysis Identifies TNS4 as a Key Effector of Cetuximab and a Regulator of the Oncogenic Activity of KRAS Mutant Colorectal Cancer Cell Lines. 31409052

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Comparison of the Clinical Sensitivity of the Idylla Platform and the OncoBEAM RAS CRC Assay for KRAS Mutation Detection in Liquid Biopsy Samples. 31222012

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer. 30661213

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Metabolic factors and the risk of colorectal cancer by KRAS and BRAF mutation status. 30613980

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Between October 2007 and May 2016, 328 patients underwent surgery for CRCs that were analyzed for KRAS mutations at a referral university hospital. 28277374

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 Biomarker BEFREE Predictive and prognostic implications of 4E-BP1, Beclin-1, and LC3 for cetuximab treatment combined with chemotherapy in advanced colorectal cancer with wild-type KRAS: Analysis from real-world data. 31057298

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts. 31771279

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 Biomarker BEFREE The proportion of HER2 amplifications in KRAS-positive CRC patients was 4.4%, which was lower than that in KRAS -negative CRC patients (14.3%). 31729406

2019

Entrez Id: 3845
Gene Symbol: KRAS
KRAS
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma
0.600 GeneticVariation BEFREE These tumors are less likely to have microsatellite instability than CRC with a V600E BRAF mutation and often harbor a KRAS or NRAS mutation. 31185985

2019